GlassScriptPhysician profile
Salma Haj-Ibrahim
NPI 1821621202
$1,742.38
in general payments reported to CMS, 2019-2025
27 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,036 · 2022: $90.64 · 2023: $115 · 2024: $241 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $615.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $600.78 | 2021-2025 | Talvey, Darzalex |
| Abbvie INC. | $276.49 | 2021-2025 | |
| Pfizer INC. | $120.82 | 2021 | |
| Amgen INC. | $98.28 | 2021 | |
| Glaxosmithkline, LLC. | $74.25 | 2021-2023 | Ojjaara |
| Ucb, INC. | $58.14 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $53.88 | 2023-2025 | Onivyde, Tazverik |
| Lilly USA, LLC | $40.76 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $39.82 | 2021-2023 | Enhertu |
| Genzyme Corporation | $37.76 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $36.99 | 2024-2025 | Keytruda, Lynparza |
| Horizon Therapeutics Plc | $29.47 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.86 | 2021 | |
| Aveo Pharmaceuticals, INC. | $23.53 | 2025 | |
| Taiho Oncology, INC. | $23.38 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $22.16 | 2025 | Epkinly |
| Daiichi Sankyo INC. | $18.21 | 2022 | |
| Dendreon Pharmaceuticals LLC | $17.92 | 2024 | Provenge |
| Mirati Therapeutics, INC. | $17.49 | 2024 | Krazati |
| Novartis Pharmaceuticals Corporation | $16.98 | 2025 | |
| Deciphera Pharmaceuticals INC. | $16.14 | 2025 | Qinlock, Tgct |
| Incyte Corporation | $15.75 | 2023 | Jakafi |
| Puma Biotechnology, INC. | $15.73 | 2024 | |
| Amneal Pharmaceuticals LLC | $15.34 | 2025 | Alymsys |
| Octapharma USA, INC. | $15.22 | 2024 | Panzyga |
| Aurinia Pharma U.S., INC. | $14.20 | 2021 | |
| Ferring Pharmaceuticals INC. | $14.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salma Haj-Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.